# US 2008/0305086 A1 · Human late stage motor neuron progenitor cells and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305086 A1
- Document ID: US20080305086A1
- Status: Published application
- Kind: A1
- Application number: 12/054,245
- Filed: 2008-03-24
- Published: 2008-12-11
- Earliest claimed: 2007-03-23
- Assignees: California Stem Cell, Inc.
- Inventors: ALEKSANDRA J. POOLE
- Web page: https://patentgrep.com/patent/US20080305086A1

## CPC

- C12N 5/0623: {Stem cells}
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Motor neuron progenitor (MNP) cells and populations of MNP cells, are provided, in particular, populations of human late stage MNP cells having a purity of greater than about 65% late stage MNP cells and high-purity populations of MNP cells having greater than 95% viable cells, as well as method of making and using the same, including deriving late stage MNP cells from pluripotent embryonic stem cells, producing high-purity populations of late stage MNP cells, producing populations of viable MNP cells, transporting viable MNP cells, and transplanting MNP cells.

## Claims

### Claim 1

An isolated population of human late stage motor neuron progenitor cells having a purity of greater than about 65% late stage motor neuron progenitor cells.

### Claim 2 (depends on 1)

The isolated population of human late stage motor neuron progenitor cells of claim 1, wherein the contaminant population is less than about 35% astrocytes.

### Claim 3 (depends on 1)

The isolated population of human late stage motor neuron progenitor cells of claim 1, having a purity of between 65% and 99% late stage motor neuron progenitor cells.

### Claim 4 (depends on 1)

The isolated population of human late stage motor neuron progenitor cells of claim 1, wherein the contaminant population is between 0% and about 35% astrocytes.

### Claim 5 (depends on 1)

The isolated population of human late stage motor neuron progenitor cells of claim 1, wherein at least a portion of the cells express two or more LIM homeobox transcription factors.

### Claim 6 (depends on 5)

The isolated population of human late stage motor neuron progenitor cells of claim 5, wherein the LIM homeobox transcription factor is HB9, Isl1, Lhx3, or Lim1.

### Claim 7 (depends on 1)

The isolated population of human late stage motor neuron progenitor cells of claim 1, wherein the cells have a calcium physiochemical profile typical of late stage motor neuron progenitor cells but absent from mature motor neurons.

### Claim 8 (depends on 1)

The isolated population of human late stage motor neuron progenitor cells of claim 1, wherein the cells express a neurofilament marker or a neuronal nuclei specific protein.

### Claim 9 (depends on 1)

The isolated population of human late stage motor neuron progenitor cells of claim 1, wherein the cells cultured on a confluent astrocytic layer generate mature motor neurons expressing one or more of SMN, SMI32 ChAT and VAChT markers.

### Claim 10 (depends on 1)

The isolated population of human late stage motor neuron progenitor cells of claim 1, wherein the cells have been transformed or transfected with a nucleic acid sequence that encodes a peptide that is not typically expressed in a non-transformed or non-transfected human motor neuron.

### Claim 11 (depends on 10)

The isolated population of human late stage motor neuron progenitor cells of claim 10, wherein the nucleic acid sequence encodes adenylyl cyclase.

### Claim 12 (depends on 1)

The isolated population of late stage motor neuron progenitor cells of claim 1, comprising cells characterized by the expression two or more LIM homeobox transcription factors and at least one of a neurofilament marker or a neuronal nuclei specific protein, and the absence of calcium channel activity.

### Claim 13 (depends on 1)

A composition formulated for injection or implantation comprising the isolated population of late stage motor neuron progenitor cells of claim 1.

### Claim 14 (depends on 1)

A test system for evaluation of a drug for treatment of a neural disease comprising the isolated population of late stage motor neuron progenitor cells of claim 1, and a drug.

### Claim 15 (depends on 14)

The test system of claim 14, wherein the test system is a kit.

### Claim 16 (depends on 1)

A cellular model of human motor neuron diseases comprising the isolated population of late stage motor neuron progenitor cells of claim 1.

### Claim 17 (depends on 1)

A method of treating a patient in need of motor neuron cells, comprising administering to the patient with the isolated population of late stage motor neuron progenitor cells of claim 1.

### Claim 18

A method of generating a high-purity population of late stage motor neuron progenitor cells wherein the population has a purity of greater than about 65% late stage motor neuron progenitor cells, comprising:
(a) neuralizing a culture of pluripotent stem cells by culturing pluripotent stem cells in a growth media supplemented with one or more of albumin, a fatty acid, a thyroid hormone, a growth factor, a vitamin, a trace mineral, insulin and transferrin,
(b) ventralizing the neuralized cell population of step (a) in a motor neuron media supplemented with retinoic acid for at least about five days.
(c) incubating the ventralized cell population of step (b) in the growth media in the absence of retinoic acid to promote formation of neurospheres;
(d) selecting the neurospheres;
(e) expanding neurospheres on an adherent substrate to form a layer of cells comprising a population of cells comprising greater than about 65% late stage motor neuron progenitor cells.

### Claim 19 (depends on 18)

The method of claim 18, wherein the growth media is a serum-free media.

### Claim 20 (depends on 18)

The method of claim 18, wherein the growth media does not contain bone morphogenic protein (BMP).

### Claim 21 (depends on 18)

The method of claim 18, wherein the motor neuron media is a serum-free media.

### Claim 22 (depends on 18)

The method of claim 18, wherein selecting the neurospheres comprises gravitational sedimentation of the neurospheres.

### Claim 23 (depends on 18)

The method of claim 18, wherein the population of late stage motor neuron progenitor cells comprises cells characterized by the expression two or more LIM homeobox transcription factors and at least one of a neurofilament marker or a neuronal nuclei specific protein, and the absence of calcium channel activity.

### Claim 24 (depends on 18)

The method of claim 18, wherein the growth factor of the growth medium is a fibroblast growth factor.

### Claim 25 (depends on 19)

The method of claim 19, wherein the serum-free growth media comprises non-essential amino acids, dipeptide L-glutamine, pyruvate, human albumin, ethanolamine, insulin, transfenin, selenite, and T3 thyroid hormone.

### Claim 26 (depends on 21)

The method of claim 21, wherein the serum-free motor neuron media comprises B27 supplement with Vitamin A, magnesium chloride, and dipeptide L-glutamine.

### Claim 27 (depends on 21)

The method of claim 21, wherein the serum-free motor neuron media is supplemented with retinoic acid at a concentration of between about 5 μM to about 20 μM.

### Claim 28 (depends on 21)

The method of claim 21, wherein the serum-free motor neuron media is further supplemented with a fibroblast growth factor.

### Claim 29 (depends on 28)

The method of claim 28, wherein the fibroblast growth factor is beta fibroblast growth factor (bFGF) at a concentration of between about 2 ng/ml to about 20 ng/ml.

### Claim 30 (depends on 18)

The method of claim 18, wherein the layer of cells comprising a population of cells having greater than about 65% late stage motor neuron progenitor cells, has a purity of between 65% and 100% late stage motor neuron progenitor cells.

### Claim 31 (depends on 18)

The method of claim 18, wherein the contaminant population in the layer of cells comprising a population of cells having greater than about 65% late stage motor neuron progenitor cells, is less than about 35% astrocytes.

### Claim 32 (depends on 18)

The method of claim 18, wherein the contaminant population in the layer of cells comprising a population of cells having greater than about 65% late stage motor neuron progenitor cells, is between 0% and about 35% astrocytes.

### Claim 33 (depends on 1)

A method for evaluating a drug candidate for treatment of a motor neuron disease comprising contacting the isolated population of late stage motor neuron progenitor cells of claim 1, with the drug candidate, and determining if the drug candidate modulates the activity or function of late stage motor neuron progenitor cells.

### Claim 34 (depends on 33)

The method of claim 33, wherein the high-purity population of late stage motor neuron progenitor cells is obtained from a subject suffering from a motor neuron disease.

### Claim 35 (depends on 34)

The method of claim 34, further comprising a high-purity population of late stage motor neuron progenitor cells obtained from a subject not suffering from a motor neuron disease, the method comprising contacting both populations of late stage motor neuron progenitor cells and determining whether the drug candidate had the same or a different effect on each population.

### Claim 36 (depends on 1)

A kit for evaluating a drug candidate for treatment of a motor neuron disease comprising, an isolated population of late stage motor neuron progenitor cells of claim 1, a drug candidate, and means for analyzing the activity or function of late stage motor neuron progenitor cells to determine if the drug candidate modulates the activity or function of late stage motor neuron progenitor cells.

### Claim 37

A method of preparing a population of viable human motor neuron progenitor cells comprising:
(a) obtaining population of human late stage motor neuron progenitor cells having a purity of greater than about 65% late stage motor neuron progenitor cells, wherein the population is cultured on an adherent substrate and provides a layer of motor neuron progenitor cells;
(b) dissociating the layer of motor neuron progenitor cells cultured on the adherent substrate to provide a cell suspension;
(c) allowing the cell suspension to rest in a non-adherent environment for a period of time sufficient for floating microspheres comprising viable cells to form;
(c) selecting the floating microspheres comprising viable cells; and
(d) collecting the microspheres to provide a population of viable human motor neuron progenitor cells.

### Claim 38 (depends on 37)

The method of claim 37, comprising enzymatically dissociating the layer of motor neuron progenitor cells.

### Claim 39 (depends on 38)

The method of claim 38, further comprising washing the cell suspension after dissociating.

### Claim 40 (depends on 37)

The method of claim 37, wherein the non-adherent environment is a low-adherent material or a material coated for minimal cell adhesion.

### Claim 41 (depends on 37)

The method of claim 37, wherein the cell suspension is allowed to rest for between at 6 hours and about 20 hours.

### Claim 42 (depends on 37)

The method of claim 37, comprising selecting the floating microspheres comprising viable cells by gravitational sedimentation of the cell suspension comprising floating microspheres, wherein the floating microspheres comprising viable cells remain in the supernatant and the nonviable cells form a pellet.

### Claim 43 (depends on 42)

The method of claim 42, comprising collecting the microspheres to provide a population of viable human motor neuron progenitor cells by collecting the supernatant.

### Claim 44 (depends on 42)

The method of claim 42, comprising a plurality of selecting steps, wherein the first selecting step comprises gravitational sedimentation of the cell suspension followed by collecting the supernatant of the sedimentation is repeated one or multiple times, a second selecting step comprises sedimentation of the supernatant collected from the first sedimentation followed by collecting the supernatant of the second sedimentation, and wherein optional subsequent selecting steps comprise sedimentation of the supernatant collected from the previous selecting step followed by collecting the supernatant.

### Claim 45 (depends on 44)

The method of claim 44, comprising three selecting steps.

### Claim 46 (depends on 37)

The method of claim 37, further comprising determining the number of viable and nonviable cells present per unit volume of solution after at least one step.

### Claim 47 (depends on 37)

The method of claim 37, wherein population of viable human motor neuron progenitor cells comprises greater than 95% viable cells.

### Claim 48 (depends on 37)

A method for determining number of viable cells in the population of viable human motor neuron progenitor cells according to claim 37, comprising:
(a) measuring the number of viable and nonviable cells in an sample of the cell suspension to determine the total number of viable and nonviable cells in the cell suspension;
(b) measuring the number of cells in sample of discarded material after each step, to determine the total number of discarded viable and nonviable cells; and
(c) determining the total number of viable cells in the supernatant containing floating microspheres, by subtracting the total number of discarded viable cells from the total number of viable cells in the cell suspension.

### Claim 49 (depends on 48)

The method of claim 48, further comprising determining the number of viable cells per unit volume of the supernatant.

### Claim 50 (depends on 37, 49)

A method for preparing a population of viable motor neuron progenitor cells prepared according to the method of claim 37, for transplantation into a subject, comprising,
(a) determining the number of cells to be transplanted;
(b) determining the volume of supernatant needed to supply the number cells to be transplanted, according to the method of claim 49;
(c) determining the total volume to be transplanted;
(d) mixing the volume of supernatant needed to supply the number cells to be transplanted with a volume of transplant vehicle needed to achieve the total volume to be transplanted.

### Claim 51 (depends on 37)

A method of treating a patient in need of motor neuron cell progenitors, comprising administering to the patient with a motor neuron disorder a population of human late stage motor neuron progenitor cells prepared according to the method of claim 37.

### Claim 52 (depends on 50)

A method of treating a patient in need of motor neuron cell progenitors, comprising administering to the patient with a motor neuron disorder a population of human late stage motor neuron progenitor cells prepared according to the method of claim 50.
